Insights from response to tyrosine kinase inhibitor therapy in a rare myeloproliferative neoplasm with CALR mutation and BCR-ABL1.
暂无分享,去创建一个
H. Kantarjian | J. Cortes | R. Luthra | S. Verstovsek | K. Patel | R. Kanagal-Shamanna | L. Medeiros | N. Pemmaraju | P. Lin | S. Loghavi | M. Mehrotra | Y. Huh
[1] J. Cayuela,et al. A CALR mutation preceding BCR-ABL1 in an atypical myeloproliferative neoplasm. , 2015, The New England journal of medicine.
[2] P. Guglielmelli,et al. Calreticulin mutation-specific immunostaining in myeloproliferative neoplasms: pathogenetic insight and diagnostic value , 2014, Leukemia.
[3] M. Cazzola,et al. JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. , 2014, Blood.
[4] A. Tefferi,et al. Type 1 vs type 2 calreticulin mutations in primary myelofibrosis: differences in phenotype and prognostic impact , 2014, Leukemia.
[5] G. Superti-Furga,et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. , 2013, The New England journal of medicine.
[6] J. D. Fitzpatrick,et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. , 2013, The New England journal of medicine.
[7] J. D. van der Walt,et al. European consensus on grading bone marrow fibrosis and assessment of cellularity. , 2005, Haematologica.